Ikena Oncology announced the resignation of Sergio Santillana and the appointment of Dr. Caroline Germa as chief medical officer, or CMO. Her addition comes at a pivotal time with the company’s focus on its clinical programs, IK-930 and IK-595, underscoring Ikena’s commitment to driving innovation in the targeted oncology space.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IKNA:
- Ikena Oncology Announces Leadership Change and Strategic Shift
- Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer
- Ikena Oncology Inc trading resumes
- iKena cuts 35% of workforce to focus on IK-930 and IK-595, to extend runway
- Ikena Oncology Outlines Key Priorities and Provides Corporate Updates
